Erratum
Erratum to “Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials”
Table 4
Vaccine efficacy values in the long-term followup of PCV clinical trials with otitis media as an endpoint . Adapted with permission from Fletcher and Fritzell, 2007 Elsevier Ltd. All rights reserved .
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
∗See Table 1 for primary otitis media endpoint, otitis media definition, myringotomy criteria, and source of MEF in each study. ∗ ∗Number of episodes in 6 months/number of episodes in 1 year. †In children diagnosed with “chronic otitis media with effusion.” ‡Efficacy against 10 or more episodes within 6 months. §Primary analysis set (see Section 3.5.2. FinOM vaccine trial). ¶Secondary analysis set (see Section 3.5.2. FinOM vaccine trial). Reported values are rounded to whole numbers; dash line indicates not reported. CI: confidence interval; ITT: intent to treat; PP: per-protocol. |